# Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL

> **NCT02212379** · PHASE2 · COMPLETED · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 170 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** raltegravir and etravirine

## Key facts

- **NCT ID:** NCT02212379
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2017-10
- **Final completion:** 2018-04
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02212379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02212379, "Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02212379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*